Navigation Links
Neuralstem to Raise $7.0 Million in Registered Direct Offering
Date:9/13/2012

ROCKVILLE, Md., Sept. 13, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today announced the pricing of a registered direct offering of 7,000,000 shares of its common stock, offered at a price to the public of $1.00 per share.  The gross proceeds to Neuralstem from this offering are expected to be $7.0 million, before deducting placement agent fees and other estimated offering expenses payable by Neuralstem.  The offering is expected to close on or about September 19, 2012, subject to customary closing conditions.

(Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

Aegis Capital Corp. is acting as sole placement agent for this offering.

The offering is being made pursuant to a shelf registration statement that Neuralstem filed with the Securities and Exchange Commission ("SEC") and is effective.  A preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC and a final prospectus supplement and accompanying base prospectus will be filed with the SEC.  When available, copies of the final prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com. Electronic copies of the final prospectus supplement and accompanying base prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, anxiety, and post-traumatic stress disorder (PTSD).

Cautionary Statement Regarding Forward Looking Information                                                        

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuralstem Announces Proposed Public Offering
2. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
3. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
5. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
6. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
7. Neuralstem Updates ALS Stem Cell Trial Progress
8. BiO2 Medical Raises $12M in Series C Funding
9. ThinkCure! Weekend At Dodger Stadium Expected To Raise Hundreds Of Thousands Of Dollars For Cancer Research
10. Retia Medical Raises $7 Million to Develop Accurate, Less-Invasive Cardiovascular Monitor
11. Midwest Health Care Startups Raise $511 Million in First Half of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... DIEGO and VANCOUVER, British Columbia, March 27, 2017 ... ) (the "Company" or "Sophiris"), a clinical late-stage ... of patients with urological diseases, today reported fourth ... key corporate highlights. Key Corporate ... Clinical Development for Localized Prostate Cancer. During 2016, ...
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
(Date:3/27/2017)... -- The staggering cost of cancer treatment means only ... the latest treatment options against cancer. Even among the ... inadequate or no health insurance and are oftentimes saddled ... modern cancer treatment is almost non-existent for cancer patients ... mission statements of pharmaceutical and biotech companies often quote ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 2017 , ... Neurotechnology , a provider of high-precision ... tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the updated  ... recognition to enable users to check in and out from anywhere via the ...
(Date:3/28/2017)... ... ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio and New ... sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National Advisory Board., ... the clinic from a small start-up to number 78 in the country based on ...
(Date:3/28/2017)... ... 28, 2017 , ... The Lice Treatment Center® booth at ... was a busy spot this year. Liz Solovay and Adrian Picheny, the firm’s ... among camp communities during the upcoming 2017 camping season. “Lice infestations at some ...
(Date:3/28/2017)... ... March 28, 2017 , ... Nurse practitioners and physician ... value increases in the healthcare workforce, according to a survey recently released by ... fairs, and candidate leads to healthcare employers of physicians and advanced practice clinicians. ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... patients for custom smile makeovers without requiring a referral. Trimble Dental ... gum disease treatment, cosmetic dentistry and dental implants. Whether patients have discolored, crooked ...
Breaking Medicine News(10 mins):